The World Health Organisation reports that half of the world's population is at risk of Malaria, and an estimated 243 million cases led to nearly 863 000 deaths in 2008.

The renewed effort to control malaria worldwide and move towards elimination in some countries is founded on the latest generation of effective tools and methods for prevention and treatment. Increasing use of long-lasting insecticide nets (LLINs), artemisinin-based combination therapies (ACTs) and indoor residual spraying (IRS) of insecticide provides an unprecedented opportunity to control and, in selected countries, eliminate malaria.

Artepharm is global leader in Artemisinin-Based Combination Therapy

Artepharm Global's leading products include the artemisinin-based combinations: the Artequick® tablet, Artequick® granules and Artemisinin raw products.

Artequick has numerous outstanding advantages, both in efficacy, course of treatment, toxicity, and convenience in usage and diversity in dosage forms. Compared to similar products, Artequick is very low-cost, has low toxicity, and is easy-to-administer with a short course of six pills. There is also an easy-to-administer children's granular formula. The most significant advantage is the low product cost as the majority of malaria patients are typically poor.

Artepharm to Eradicate Malaria in Comoros Islands, East Africa

The Comoros Islands are a small chain of islands in East Africa (population 800,000) in which 28% of the residents are infected with Malaria. In 2007 Artepharm with its patented ArteQuick Malaria treatment reduced the Malaria rate on the Comoros Island of Moheli from over 20% of the population to less than 1%. Strict Procedural controls will be deployed with this upcoming trial on the rest of the Comoros Islands with the intent of attracting support from the World Health Organisation to back ArteQuick has the leading Global treatment for Malaria.

Artepharm Global

Tag Cloud